Servier Pharmaceuticals shared on LinkedIn:
“We’re pleased to announce that the first patients have been dosed in the pivotal Phase 2 EMBLEM-1 cohort of a Phase 1/2 study evaluating our investigational antibody drug conjugate (ADC) in patients with aggressive adenoid cystic carcinoma (ACC).
This milestone underscores the momentum of Servier’s growing oncology portfolio and our commitment to bringing scientific rigor and meaningful innovation to rare cancers where patients face significant unmet need.”
Other articles about antibody drug conjugate on OncoDaily.